In a bid to bolster its rare disease pipeline, Sanofi has agreed to acquire all the assets and liabilities associated with INBRX-101, for the treatment of patients with alpha-1 antitrypsin deficiency. Through the deal, which is worth up to US$2.2 B, Sanofi will create a new company which will include three anti-cancer molecules and provide funds to develop these assets. Interestingly in September 2023, Chiesi declined to exercise its option for the ex-North American rights from Inhibrx to develop and commercialise INBRX-101 for the treatment of patients with emphysema due to alpha-1 antitrypsin deficiency.